Trial Profile
An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2019
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2019 This trial has been completed in Netherlands.
- 02 Feb 2019 The trial has been completed in the Spain, according to European Clinical Trials Database.